Hubbry Logo
GabapentinGabapentinMain
Open search
Gabapentin
Community hub
Gabapentin
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Gabapentin
Gabapentin
Gabapentin
View on Wikipedia
from Wikipedia

Gabapentin
Gabapentin.acid
Clinical data
Trade namesNeurontin, others[1]
Other namesCI-945; GOE-3450; DM-1796 (Gralise)
AHFS/Drugs.comMonograph
MedlinePlusa694007
License data
Pregnancy
category
Dependence
liability		Physical: High[3]
Psychological: Moderate
Addiction
liability		Low[4]
Routes of
administration		By mouth
Drug classGabapentinoid
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability27–60% (inversely proportional to dose; a high-fat meal also increases bioavailability)[8][9]
Protein bindingLess than 3%[8][9]
MetabolismNot significantly metabolized[8][9]
Elimination half-life5 to 7 hours[8][9]
ExcretionKidney[8][9]
Identifiers
  • 2-[1-(Aminomethyl)cyclohexyl]acetic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard100.056.415 Edit this at Wikidata
Chemical and physical data
FormulaC9H17NO2
Molar mass171.240 g·mol−1
3D model (JSmol)
  • O=C(O)CC1(CN)CCCCC1
  • InChI=1S/C9H17NO2/c10-7-9(6-8(11)12)4-2-1-3-5-9/h1-7,10H2,(H,11,12) checkY
  • Key:UGJMXCAKCUNAIE-UHFFFAOYSA-N checkY
  (verify)

Gabapentin, is a central nervous system depressant and a structural analog and derivative of GABA (γ-Aminobutyric acid). Specifically a synthetic analog, meaning it was designed to mimic the structure and effects of the inhibitory neurotransmitter GABA. Primarily used to treat neuropathic pain and also for partial seizures[10][7] of epilepsy. It is a commonly used medication for the treatment of neuropathic pain caused by diabetic neuropathy, postherpetic neuralgia, and central pain.[11] It is moderately effective: about 30–40% of those given gabapentin for diabetic neuropathy or postherpetic neuralgia have a meaningful benefit.[12] Gabapentin is commonly prescribed off-label as a Anxiolytic or anti-anxiety medication, although not as effective as Pregabalin in this regard, especially for Generalized Anxiety Disorder (GAD), as gabapentin is more effective for Social Anxiety Disorder (SAD).[13][14]

Gabapentin, like other gabapentinoid drugs, acts by decreasing activity of the α2δ-1 protein, coded by the CACNA2D1 gene, first known as an auxiliary subunit of voltage-gated calcium channels.[15][16][17] However, see Pharmacodynamics, below. By binding to α2δ-1, gabapentin reduces the release of excitatory neurotransmitters (primarily glutamate) and as a result, reduces excess excitation of neuronal networks in the spinal cord and brain. Sleepiness and dizziness are the most common side effects. Serious side effects include respiratory depression and allergic reactions.[7] As with all other antiepileptic drugs approved by the FDA, gabapentin is labeled for an increased risk of suicide. Lower doses are recommended in those with kidney disease.[7]

Gabapentin was first approved for use in the United Kingdom in 1993.[18] It has been available as a generic medication in the United States since 2004.[19] It is the first of several other drugs that are similar in structure and mechanism, called gabapentinoids. In 2023, it was the ninth most commonly prescribed medication in the United States, with more than 45 million prescriptions.[20][21] During the 1990s, Parke-Davis, a subsidiary of Pfizer, used several illegal techniques to encourage physicians in the United States to prescribe gabapentin for unapproved uses.[22] They have paid out millions of dollars to settle lawsuits regarding these activities.[23]

Medical uses

[edit]

Gabapentin is recommended for use in focal seizures and neuropathic pain.[7][10] Gabapentin is prescribed off-label in the US and the UK,[24][25] for example, for the treatment of non-neuropathic pain,[24] anxiety disorders, sleep problems and bipolar disorder.[26] In recent years, gabapentin has seen increased use, particularly in the elderly.[27] There is concern regarding gabapentin's off-label use due to the lack of strong scientific evidence for its efficacy in multiple conditions, its proven side effects and its potential for misuse and physical/psychological dependency.[13][14][3] Some harms, including nervous system harms, have been underreported in published trials of gabapentin, potentially resulting in the underestimation of harms in guidelines for the use of gabapentin.[28]

Seizures

[edit]

Gabapentin is approved for the treatment of focal seizures;[29] however, it is not effective for generalized epilepsy.[30]

Neuropathic pain

[edit]

Gabapentin is recommended as a first-line treatment for chronic neuropathic pain by various medical authorities.[10][11][31][32] This is a general recommendation applicable to all neuropathic pain syndromes except for trigeminal neuralgia, where it may be used as a second- or third-line agent.[11][32]

Regarding the specific diagnoses, a systematic review has found evidence for gabapentin to provide pain relief for some people with postherpetic neuralgia and diabetic neuropathy.[12] Gabapentin is approved for the former indication in the US.[7] In addition to these two neuropathies, European Federation of Neurological Societies guideline notes gabapentin effectiveness for central pain.[11] A combination of gabapentin with an opioid or nortriptyline may work better than either drug alone.[11][32]

Gabapentin shows substantial benefit (at least 50% pain relief or a patient's global impression of change (PGIC) "very much improved") for neuropathic pain (postherpetic neuralgia or peripheral diabetic neuropathy) in 30–40% of subjects treated as compared to those treated with placebo.[12]

Evidence finds little or no benefit and significant risk in those with chronic low back pain or sciatica.[33][34] Gabapentin is not effective in HIV-associated sensory neuropathy[35] and neuropathic pain due to cancer.[36]

Anxiety

[edit]

There is a small amount of research on the use of gabapentin for the treatment of anxiety disorders.[37][38]

Gabapentin is effective for the long-term treatment of social anxiety disorder and in reducing preoperative anxiety.[13][14]

In a controlled trial of breast cancer survivors with anxiety,[38] and a trial for social phobia,[37] gabapentin significantly reduced anxiety levels.

For panic disorder, gabapentin has produced mixed results.[38][37][14]

Sleep

[edit]

Gabapentin is effective in treating sleep disorders such as insomnia and restless legs syndrome that are the result of an underlying illness, but comes with some risk of discontinuation and withdrawal symptoms after prolonged use at higher doses.[39]

Gabapentin enhances slow-wave sleep in people with primary insomnia. It also improves sleep quality by elevating sleep efficiency and decreasing spontaneous arousal.[40]

Drug dependence

[edit]

Gabapentin is moderately effective in reducing the symptoms of alcohol withdrawal and associated craving.[41][42][43] The evidence in favor of gabapentin is weak in the treatment of alcoholism: it does not contribute to the achievement of abstinence, and the data on the relapse of heavy drinking and percent of days abstinent do not robustly favor gabapentin; it only decreases the percent days of heavy drinking.[44]

Gabapentin is ineffective in cocaine dependence and methamphetamine use,[45] and it does not increase the rate of smoking cessation.[46] While some studies indicate that gabapentin does not significantly reduce the symptoms of opiate withdrawal, there is increasing evidence that gabapentinoids are effective in controlling some of the symptoms during opiate detoxification. A clinical study in Iran, where heroin dependence is a significant social and public health problem, showed gabapentin produced positive results during an inpatient therapy program, particularly by reducing opioid-induced hyperalgesia and drug craving.[47][45] There is insufficient evidence for its use in cannabis dependence.[48]

Other

[edit]

Gabapentin is recommended as a first-line treatment of the acquired pendular nystagmus, torsional nystagmus, and infantile nystagmus; however, it does not work in periodic alternating nystagmus.[49][50][51]

Gabapentin decreases the frequency of hot flashes in both menopausal women and people with breast cancer. However, antidepressants have similar efficacy, and treatment with estrogen more effectively prevents hot flashes.[52]

Gabapentin reduces spasticity in multiple sclerosis and is prescribed as one of the first-line options.[53] It is an established treatment of restless legs syndrome.[54] Gabapentin alleviates itching in kidney failure (uremic pruritus)[55][56] and itching of other causes.[57] It may be an option in essential or orthostatic tremor.[58][59][60]

Gabapentin does not appear to provide benefit for bipolar disorder,[14][42][61] complex regional pain syndrome,[62] post-surgical pain,[63] or tinnitus,[64] or prevent episodic migraine in adults.[65]

Contraindications

[edit]

Gabapentin should be used carefully and at lower doses in people with kidney problems due to possible accumulation and toxicity. It is unclear if it is safe during pregnancy or breastfeeding.[7]

Side effects

[edit]

In a systematic review analysing data from 5 cohort studies having 10,85,488 patients, use of gabapentinoids (gabapentin and pregabalin) was associated with an increased risk of thrombotic events (deep venous thrombosis and pulmonary thrombo-embolism) as early as three months of use, and with increased risk of cardiovascular events on prolonged use of more than a year duration. Heart failure was not increased with the use of gabapentinoids.[66]

Gabapentin Orion 100 mg, bottle and pills in Sweden

Dizziness and somnolence are the most frequent side effects.[7] Fatigue, ataxia, peripheral edema (swelling of extremities), and nystagmus are also common.[7] A 2017 meta-analysis found that gabapentin also increased the risk of difficulties in mentation and visual disturbances as compared to a placebo.[33] Gabapentin is associated with a weight gain of 2.2 kg (4.9 lb) after 1.5 months of use.[67] Case studies indicate that it may cause anorgasmia and erectile dysfunction,[68] as well as myoclonus[69][70] that disappear after discontinuing gabapentin or replacing it with other medication. Fever, swollen glands that do not go away, eyes or skin turning yellow, unusual bruises or bleeding, unexpected muscle pain or weakness, rash, long-lasting stomach pain which may indicate an inflamed pancreas, hallucinations, anaphylaxis, respiratory depression, and increased suicidal ideation are rare but serious side effects.[71]

Suicide

[edit]

As with all antiepileptic drugs approved in the US, gabapentin label contains a warning of an increased risk of suicidal thoughts and behaviors.[7] This warning is based on a meta-analysis of all approved antiepileptic drugs in 2008, and not with gabapentin alone.[72] According to an experimental meta-analysis of insurance claims databases, gabapentin use is associated with an approximately 40% increased risk of suicide, suicide attempt, and violent death as compared with a reference anticonvulsant drug topiramate. The risk is increased for people with bipolar disorder or epilepsy.[72] Another study has shown an approximately doubled rate of suicide attempts and self-harm in people with bipolar disorder who are taking gabapentin versus those taking lithium.[73] A large Swedish study suggests that gabapentinoids are associated with an increased risk of suicidal behaviour, unintentional overdoses, head/body injuries, and road traffic incidents and offences.[74] On the other hand, a study published by the Harvard Data Science Review found that gabapentin was associated with a significantly reduced rate of suicide.[75]

Respiratory depression

[edit]

Serious breathing suppression, potentially fatal, may occur when gabapentin is taken together with opioids, benzodiazepines, or other depressants, or by people with underlying lung problems such as COPD.[76] Gabapentin and opioids are commonly prescribed or abused together, and research indicates that the breathing suppression they cause is additive. For example, gabapentin use before joint replacement or laparoscopic surgery increased the risk of respiratory depression by 30–60%.[76] A Canadian study showed that use of gabapentin and other gabapentinoids, whether for epilepsy, neuropathic pain or other chronic pain was associated with a 35–58% increased risk for severe exacerbation of pre-existing chronic obstructive pulmonary disease.[77]

Withdrawal and dependence

[edit]

Withdrawal symptoms typically occur 1–2 days after abruptly stopping gabapentin (almost unambiguously due to extended use and during a very short-term rebound phenomenon) — similar to, albeit less intense than most benzodiazepines.[78] Agitation, confusion and disorientation are the most frequently reported, followed by gastrointestinal complaints and sweating, and more rare tremor, tachycardia, hypertension and insomnia.[78] In some cases, users experience withdrawal seizures after chronic or semi-chronic use in the absence of periodic cycles or breaks during repeating and consecutive use.[79] All these symptoms subside when gabapentin is re-instated[78] or tapered off gradually at an appropriate rate.[citation needed]

On its own, gabapentin appears not to have a substantial addictive power. In human and animal experiments, it shows limited to no rewarding effects. The vast majority of people abusing gabapentin are current or former abusers of opioids or sedatives.[79] In these persons, gabapentin can boost the opioid "high" as well as decrease commonly experienced opioid-withdrawal symptoms such as anxiety.[80]

Psychiatric and behavioral adverse effects

[edit]

Gabapentin is increasingly recognized to cause a range of psychiatric and behavioral adverse effects that extend beyond its more common neurological side effects. Systematic reviews have documented atypical manifestations such as aggression, agitation, irritability, mood instability, and suicidal ideation, with some cases noting the emergence of mania, hallucinations, and psychosis, particularly in pediatric populations and individuals with preexisting psychiatric conditions.[81][82][83]

Large cohort studies and post-marketing surveillance indicate that neuropsychiatric symptoms—including confusion, depression, and behavioral disturbances—can occur in up to 29% of gabapentin users. Most reactions are mild to moderate and often dose-dependent.[84] There is also evidence associating gabapentin with an increased risk of suicidal behavior, especially in younger patients, and rare reports of violent or aggressive behavior. Causality is difficult to establish, and such events remain uncommon.[85][86]

Overdose

[edit]

Through excessive ingestion, accidental or otherwise, persons may experience overdose symptoms including drowsiness, sedation, blurred vision, slurred speech, somnolence, uncontrollable jerking motions, and anxiety. A very high amount taken is associated with breathing suppression, coma, and possibly death, particularly if combined with alcohol or opioids.[79][87]

Pharmacology

[edit]

Animal models

[edit]

Gabapentin prevents seizures in a dose-related manner in several laboratory animal models.[88] These models include spinal extensor seizures from low-intensity electroshock to the forebrain in mice, maximal electroshock in rats, spinal extensor seizures in DBA/2 mice with a genetic sensitivity to seizures induced by loud noise, and in rats "kindled" to produce focal seizures by repeated prior electrical stimulation of the hippocampus. Gabapentin slightly increased spontaneous absence-like seizures in a genetically susceptible strain recorded with electroencephalography. All of these effects of gabapentin were seen at dosages at or below the threshold for producing ataxia.

Gabapentin has also been tested in a wide variety of animal models that are relevant for analgesic actions.[89] Generally, gabapentin is not active to prevent pain-related behaviors in models of acute nociceptive pain. It prevents pain-related behaviors when animals are made sensitive by prior peripheral inflammation or peripheral nerve damage (inflammatory or neuropathic conditions).

Pharmacodynamics

[edit]

Gabapentin is a ligand of the α2δ calcium channel subunit.[90][91] The α2δ-1 protein is coded by the CACNA2D1 gene. α2δ was first described as an auxiliary protein connected to the main α1 subunit (the channel-forming protein) of high voltage activated voltage-dependent calcium channels (L-type, N-type, P/Q type, and R-type).[15] The same α2δ protein has more recently been shown to interact directly with some NMDA-type and AMPA-type glutamate receptors at presynaptic sites and also with thrombospondin (an extracellular matrix protein secreted by astroglial cells).[92]

Gabapentin is not a direct calcium channel blocker: it exerts its actions by disrupting the regulatory function of α2δ and its interactions with other proteins. Gabapentin reduces delivery of intracellular calcium channels to the cell membrane, reduces the activation of the channels by the α2δ subunit, decreases signaling to lead to neurotransmitters release, and disrupts interactions of α2δ with voltage gated calcium channels but also with NMDA receptors, neurexins, and thrombospondin.[15][16][17] These proteins are found as mutually interacting parts of the presynaptic active zone, where numerous protein molecules interact with each other to enable and to regulate the release of neurotransmitters from presynaptic vesicles into the synaptic space.[citation needed]

Out of the four known isoforms of α2δ protein, gabapentin binds with similar high affinity to two: α2δ-1 and α2δ-2.[91] All of the pharmacological properties of gabapentin tested to date are explained by its binding to just one isoform – α2δ-1.[91][16]

The endogenous α-amino acids L-leucine and L-isoleucine, which resemble gabapentin in chemical structure, bind α2δ with similar affinity to gabapentin and are present in human cerebrospinal fluid at micromolar concentrations.[93] They may be the endogenous ligands of the α2δ subunit, and they competitively antagonize the effects of gabapentin.[93][94] Accordingly, while gabapentin has nanomolar affinity for the α2δ subunit, its potency in vivo is in the low micromolar range, and competition for binding by endogenous L-amino acids is likely to be responsible for this discrepancy.[16]

Gabapentin is a potent activator of voltage-gated potassium channels KCNQ3 and KCNQ5, even at low nanomolar concentrations. However, this activation is unlikely to be the dominant mechanism of gabapentin's therapeutic effects.[95]

Gabapentin is structurally similar to the neurotransmitter glutamate and competitively inhibits branched-chain amino acid aminotransferase (BCAT), slowing down the synthesis of glutamate.[96] In particular, it inhibits BCAT-1 at high concentrations (Ki = 1 mM), but not BCAT-2.[97] At very high concentrations, gabapentin can suppress the growth of cancer cells, presumably by affecting mitochondrial catabolism; however, the precise mechanism remains elusive.[97]

Even though gabapentin is a structural GABA analogue, and despite its name, it does not bind to the GABA receptors, does not convert into GABATooltip γ-aminobutyric acid or another GABA receptor agonist in vivo, and does not modulate GABA transport or metabolism within the range of clinical dosing.[90] In vitro gabapentin has been found to very weakly inhibit the GABA aminotransferase enzyme (Ki = 17–20 mM); however, this effect is so weak that it is not clinically relevant at prescribed doses.[96]

Pharmacokinetics

[edit]

Gabapentin is absorbed from the intestines by an active transport process mediated via an amino acid transporter, presumably, LAT2.[98] As a result, the pharmacokinetics of gabapentin is dose-dependent, with diminished bioavailability and delayed peak levels at higher doses.[91]

The oral bioavailability of gabapentin is approximately 80% at 100 mg administered three times daily once every 8 hours, but decreases to 60% at 300 mg, 47% at 400 mg, 34% at 800 mg, 33% at 1,200 mg, and 27% at 1,600 mg, all with the same dosing schedule.[7][99] Drugs that increase the transit time of gabapentin in the small intestine can increase its oral bioavailability; when gabapentin was co-administered with oral morphine, the oral bioavailability of a 600 mg dose of gabapentin increased by 50%.[99]

Gabapentin at a low dose of 100 mg has a Tmax (time to peak levels) of approximately 1.7 hours, while the Tmax increases to 3 to 4 hours at higher doses.[91] Food does not significantly affect the Tmax of gabapentin and increases the Cmax and area-under-curve levels of gabapentin by approximately 10%.[99]

Gabapentin can cross the blood–brain barrier and enter the central nervous system.[90] Gabapentin concentration in cerebrospinal fluid is approximately 9–14% of its blood plasma concentration.[99] Due to its low lipophilicity,[99] gabapentin requires active transport across the blood–brain barrier.[100][90][101][102] The LAT1 is highly expressed at the blood–brain barrier[103] and transports gabapentin across into the brain.[100][90][101][102] As with intestinal absorption mediated by an amino acid transporter, the transport of gabapentin across the blood–brain barrier by LAT1 is saturable.[100] Gabapentin does not bind to other drug transporters such as P-glycoprotein (ABCB1) or OCTN2 (SLC22A5).[100] It is not significantly bound to plasma proteins (<1%).[99]

Gabapentin undergoes little or no metabolism.[91][99]

Gabapentin is generally safe in people with liver cirrhosis.[104]

Gabapentin is eliminated renally in the urine.[99] It has a relatively short elimination half-life, with the reported average value of 5 to 7 hours.[99] Because of its short elimination half-life, gabapentin must be administered 3 to 4 times per day to maintain therapeutic levels.[105] Gabapentin XR (brand name Gralise) is taken once a day.[106]

Chemistry

[edit]
Chemical structures of GABA and gabapentin, with commonalities highlighted

Gabapentin is a 3,3-disubstituted derivative of GABA. Therefore, it is a GABA analogue, as well as a γ-amino acid.[107][108] It is similar to several other compounds that collectively are called gabapentinoids. Specifically, it is a derivative of GABA with a pentyl disubstitution at 3 position, hence, the name - gabapentin, in such a way as to form a six-membered ring. After the formation of the ring, the amine and carboxylic groups are not in the same relative positions as they are in the GABA;[109] they are more conformationally constrained.[110]

Although it has been known for some time that gabapentin must bind to the α2δ-1 protein in order to act pharmacologically (see Pharmacodynamics), the three-dimensional structure of the α2δ-1 protein with gabapentin bound (or alternatively, the native amino acid, L-Isoleucine bound) has only recently been obtained by cryo-electron microscopy.[111] A figure of this drug-bound structure is shown in the Chemistry section of the entry on gabapentinoid drugs. This study confirms other findings to show that both compounds alternatively can bind at a single extracellular site (somewhat distant from the calcium conducting pore of the voltage gated calcium channel α1 subunit) on the calcium channel and chemotaxis (Cache1) domain of α2δ-1.

Synthesis

[edit]
Synthesis of gabapentin

A process for chemical synthesis and isolation of gabapentin with high yield and purity[112] starts with conversion of 1,1-cyclohexanediacetic anhydride to 1,1-cyclohexanediacetic acid monoamide and is followed by a 'Hofmann' rearrangement in an aqueous solution of sodium hypobromite prepared in situ.

History

[edit]

GABA is the principal inhibitory neurotransmitter in mammalian brains. By the early 1970s, it was appreciated that there are two main classes of GABA receptors, GABAA and GABAB and also that baclofen was an agonist of GABAB receptors. Gabapentin was designed, synthesized, and tested in mice by researchers at the pharmaceutical company Goedecke AG in Freiburg, Germany (a subsidiary of Parke-Davis). It was meant to be an analogue of the neurotransmitter GABA that could more easily cross the blood–brain barrier. It was first synthesized in 1974/75 and described in 1975[113] by Satzinger and Hartenstein.[109][114]

The first pharmacology findings published were sedating properties and prevention of seizures in mice evoked by the GABA antagonist, thiosemicarbazide.[113] Shortly after, gabapentin was shown in vitro to reduce the release of the neurotransmitter dopamine from slices of rat caudate nucleus (striatum).[115] This study provided evidence that the action of gabapentin, unlike baclofen, did not arise from the GABAB receptor.

Initial clinical trials utilizing small numbers of subjects were for treatment of spasticity[116] and migraine[117] but neither study had statistical power to allow conclusions. In 1987, the first positive results with gabapentin were obtained in a clinical trial using three dose groups versus pre-treatment seizure frequency for 75 days, as add-on treatment in patients who still had seizures despite taking other medications.[118] This study did not show statistically significant results. It did show a strong dose-related trend to decreased frequency of seizures.

Under the brand name Neurontin, it was first approved in the United Kingdom in May 1993, for the treatment of refractory epilepsy.[119] Approval by the U.S. Food and Drug Administration followed in December 1993, also for use as an adjuvant (effective when added to other antiseizure drugs) medication to control partial seizures in adults; that indication was extended to children in 2000.[120][7] Subsequently, gabapentin was approved in the United States for the treatment of pain from postherpetic neuralgia in 2002.[121] A generic version of gabapentin first became available in the United States in 2004.[19] An extended-release formulation of gabapentin for once-daily administration, under the brand name Gralise, was approved in the United States for the treatment of postherpetic neuralgia in January 2011.[122][123]

In recent years, gabapentin has been prescribed for an increasing range of disorders and is one of the more common medications used, particularly in elderly people.[124]

Society and culture

[edit]
[edit]

United Kingdom

[edit]

Effective April 2019, the United Kingdom reclassified the drug as a class C controlled substance.[125][126][127][128][129]

United States

[edit]

Gabapentin is not a controlled substance under the federal Controlled Substances Act.[130] Effective 1 July 2017, Kentucky classified gabapentin as a Schedule V controlled substance statewide.[131] Gabapentin is a schedule V drug in other states such as West Virginia,[132] Tennessee,[133] Alabama,[134] Utah,[135] and Virginia.[136]

Off-label promotion

[edit]

Although some small, non-controlled studies in the 1990s—mostly sponsored by gabapentin's manufacturer—suggested that treatment for bipolar disorder with gabapentin may be promising,[137] the preponderance of evidence suggests that it is not effective.[138]

Franklin v. Parke-Davis case

[edit]

Main article: Franklin v. Parke-Davis

After the corporate acquisition of the original patent holder, the pharmaceutical company Pfizer admitted that there had been violations of FDA guidelines regarding the promotion of unproven off-label uses for gabapentin in the Franklin v. Parke-Davis case.

While off-label prescriptions are common for many drugs, marketing of off-label uses of a drug is not.[22] In 2004, Warner-Lambert (which subsequently was acquired by Pfizer) agreed to plead guilty for activities of its Parke-Davis subsidiary, and to pay $430 million in fines to settle civil and criminal charges regarding the marketing of Neurontin for off-label purposes. The 2004 settlement was one of the largest in U.S. history up to that point, and the first off-label promotion case brought successfully under the False Claims Act.[139]

Kaiser Foundation Hospitals and Kaiser Foundation Health Plan sued Pfizer Inc., alleging that the pharmaceutical company had misled Kaiser by recommending Neurontin as an off-label treatment for certain conditions (including bipolar disorder, migraines, and neuropathic pain).[140][141][142] In 2010, a federal jury in Massachusetts ruled in Kaiser's favor, finding that Pfizer violated the federal Racketeer Influenced and Corrupt Organizations (RICO) Act and was liable for US$47.36 million in damages, which was automatically trebled to just under $142.1 million.[141][140] Aetna, Inc. and a group of employer health plans prevailed in their similar Neurontin-related claims against Pfizer.[143] Pfizer appealed, but the U.S. Court of Appeals for the First Circuit upheld the verdict,[143] and in 2013, the US Supreme Court declined to hear the case.[144][145]

Gabasync

[edit]

Gabasync, a treatment consisting of a combination of gabapentin and two other medications (flumazenil and hydroxyzine) as well as therapy, is an ineffective treatment promoted for methamphetamine addiction. It had also been claimed to be effective for dependence on alcohol or cocaine.[146] It was marketed as PROMETA. While the FDA has approved individual drugs, they have not approved their off-label use for addiction treatment.[147] Gabasync was marketed by Hythiam, Inc., which is owned by Terren Peizer, a former junk bond salesman who has since been convicted of securities fraud relative to another company.[148][149][150][146] Hythiam charges up to $15,000 per patient to license its use (of which half goes to the prescribing physician, and half to Hythiam).[151]

In a November 2005 article entitled "Curb Your Cravings For This Stock", Barrons wrote: "If the venture works out for patients and the investing public, it'll be a rare success for Peizer, who's promoted a series of disappointing small-cap medical or technology stocks ... since his days at Drexel".[152] 60 Minutes, NBC News, and The Dallas Morning News criticized Peizer after the company bypassed clinical studies and government approval when bringing to market Prometa; the addiction drug proved to be completely ineffective.[153][154][146][155] CBS News journalist Scott Pelley said to Peizer in 2007: "Depending on who you talk to, you're either a revolutionary or a snake oil salesman."[156][152] Journalist Adam Feuerstein opined: "most of what Peizer says is dubious-sounding hype".[157]

In November 2011, the results of a double-blind, placebo-controlled study (financed by Hythiam and carried out at UCLA) were published in the peer-reviewed journal Addiction. It concluded that Gabasync is ineffective: "The PROMETA protocol, consisting of flumazenil, gabapentin, and hydroxyzine, appears to be no more effective than placebo in reducing methamphetamine use, retaining patients in treatment, or reducing methamphetamine craving."[158]

[edit]

The consumption of gabapentinoids rose significantly between 2008 and 2018. A study published in Nature Communications in 2023 highlights this trend, demonstrating a notable escalation in sales of gabapentinoids. The study, which analyzed healthcare data across 65 countries/ regions, found that the consumption rate of gabapentinoids had doubled over the decade, driven by their use in a wide range of indications.[159]

Brand names

[edit]

Gabapentin was originally marketed under the brand name Neurontin. Since it became generic, it has been marketed worldwide using over 300 different brand names.[1] An extended-release formulation of gabapentin for once-daily administration was introduced in 2011 for postherpetic neuralgia under the brand name Gralise.[160]

In the US, Neurontin is marketed by Viatris after Upjohn was spun off from Pfizer.[161][162][163]

[edit]

Parke-Davis developed a drug called pregabalin, which is related in structure to gabapentin, as a successor to gabapentin.[164] Another similar drug atagabalin has been unsuccessfully tried by Pfizer as a treatment for insomnia.[165] A prodrug form (gabapentin enacarbil)[166] was approved by the U.S. Food and Drug Administration (FDA).

Recreational use

[edit]

When taken in excess, gabapentin can induce euphoria, a sense of calm, improved sociability, and reduced alcohol or cocaine cravings.[167][168][169] Also known on the streets as "Gabbies",[170] gabapentin was reported in 2017 to be increasingly abused and misused for these euphoric effects.[171][172] About 1 percent of the responders to an Internet poll and 22 percent of those attending addiction facilities had a history of abuse of gabapentin.[78][173] Gabapentin misuse, toxicity, and use in suicide attempts among adults in the US increased from 2013 to 2017.[174]

After Kentucky implemented stricter legislation regarding opioid prescriptions in 2012, there was an increase in gabapentin-only and multi-drug use from 2012 to 2015. The majority of these cases were from overdose in suspected suicide attempts. Increases in abuse and recreational use accompanied these rates.[175]

Withdrawal symptoms, often resembling those of benzodiazepine withdrawal, play a role in the physical dependence some users experience.[79] Its misuse predominantly coincides with the usage of other CNS depressant drugs, namely opioids, benzodiazepines, and alcohol.[176]

Veterinary use

[edit]

In cats, gabapentin can be used as an analgesic in multi-modal pain management,[177] anxiety medication to reduce stress during travel or vet visits,[178] and anticonvulsant.[179]

Veterinarians may prescribe gabapentin as an anticonvulsant and pain reliever in dogs.[180][179] It has beneficial effects for treating epilepsy, different kinds of pain (chronic, neuropathic, and post-operative pain), and anxiety, lip-licking behavior, storm phobia, fear-based aggression.[181][182]

It is also used to treat chronic pain-associated nerve inflammation in horses and dogs. Side effects include tiredness and loss of coordination, but these effects generally resolve within 24 hours of starting the medication.[180][179]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Gabapentin

View on Grokipedia
from Grokipedia
Gabapentin is an anticonvulsant medication structurally analogous to the neurotransmitter gamma-aminobutyric acid (GABA), approved by the U.S. Food and Drug Administration (FDA) in 1993 as adjunctive therapy for partial-onset seizures in patients with epilepsy. Its chemical structure features a cyclohexane ring substituted with aminomethyl and carboxymethyl groups, distinguishing it from GABA while enabling oral bioavailability and central nervous system penetration. In 2002, the FDA expanded approval to include management of postherpetic neuralgia in adults, a form of neuropathic pain following shingles. Although its precise mechanism remains incompletely elucidated, gabapentin primarily binds to the alpha-2-delta subunit of voltage-gated calcium channels, thereby inhibiting calcium influx and reducing excitatory neurotransmitter release without direct agonism at GABA receptors. Gabapentin is extensively prescribed off-label for conditions such as diabetic neuropathy, fibromyalgia, restless legs syndrome, and anxiety disorders, despite variable empirical support for efficacy in these applications. Notable controversies surround its potential for misuse and abuse, particularly among individuals with substance use histories, where it is often combined with opioids or benzodiazepines to enhance euphoric effects, contributing to dependence and overdose risks as documented in systematic reviews of clinical and population data. This has prompted regulatory discussions, with some jurisdictions imposing controls akin to scheduling, reflecting empirical evidence of diversion and non-medical use prevalence rates up to 13-15% in certain high-risk cohorts.

Therapeutic Uses

Approved Indications

Gabapentin is approved by the U.S. (FDA) as an adjunctive therapy for the treatment of partial s with or without secondary generalization in patients aged 3 years and older. This approval, granted in 1993 under the brand name Neurontin, applies to management where gabapentin is used in combination with other medications to reduce frequency. The typical posology in adults and children over 6 years begins with an initial dose of 300 mg per day, gradually increased to 900–3600 mg per day divided into three doses, with adjustments for children based on body weight. Additionally, the FDA approved gabapentin in 2002 for the management of (PHN), a condition resulting from (herpes zoster) reactivation, specifically in adults. This indication targets moderate-to-severe pain persisting after the shingles rash has resolved, with formulations like Gralise optimized for once-daily dosing in this context. A similar posology is used for neuropathic pain, including postherpetic neuralgia and painful diabetic peripheral neuropathy (the latter off-label in the US), starting at 300 mg per day and titrating according to response and tolerance up to 3600 mg per day. Approvals by other regulatory agencies, such as the , align closely, authorizing gabapentin for similar epilepsy adjunctive therapy and PHN uses in adults. Specific extended-release formulations, such as (Horizant), have separate FDA approvals for PHN and moderate-to-severe primary in adults, but these pertain to the form rather than immediate-release gabapentin. No broad pediatric approval exists for PHN, and gabapentin's indication requires careful dosing adjustments based on age and weight in children.

Off-Label Applications

Gabapentin is frequently prescribed off-label for various psychiatric conditions, including anxiety disorders, , and , despite limited high-quality evidence supporting its efficacy in these applications. In outpatient psychiatric settings, gabapentin use for anxiety was documented in approximately 3.5% of relevant visits from 2011 to 2016, often alongside other depressants, though randomized controlled trials show inconsistent benefits and highlight risks of augmentation rather than standalone treatment. For , early reports from the 1990s promoted its adjunctive role in stabilization, but subsequent reviews indicate modest effects at best, with no superiority over in large-scale trials and concerns over industry-influenced outcome reporting in sponsored studies. In pain management beyond approved postherpetic neuralgia, gabapentin is commonly used off-label for , prophylaxis, and other neuropathic or musculoskeletal pains, accounting for a significant portion of prescriptions in academic centers, with the maximum daily dose for fibromyalgia typically 2400 mg divided into three doses (e.g., 800 mg three times daily), starting low and titrated based on response and tolerability. Evidence for is minimal, with small trials suggesting short-term pain reduction but no clinically meaningful long-term benefits compared to , and holding specific approval for this indication instead. prevention trials, often industry-funded, reported positive secondary outcomes but primary endpoints frequently failed, raising questions about selective reporting and true efficacy. Restless legs syndrome (RLS) represents another prevalent off-label use, particularly in patients with comorbidities like renal impairment where dopamine agonists are contraindicated, though gabapentin enacarbil (a prodrug) holds specific FDA approval for moderate-to-severe RLS while standard gabapentin relies on extrapolated data from smaller studies showing symptom relief via calcium channel modulation; off-label dosages for immediate-release gabapentin typically range from 300-1800 mg/day, often starting low at 100-300 mg at bedtime and titrated, whereas gabapentin enacarbil is dosed at 600 mg once daily around 5 PM. Additional off-label applications include alcohol dependence and withdrawal, where some evidence from randomized trials supports reduced cravings and symptoms as an adjunct, but systematic reviews emphasize insufficient data for routine recommendation due to abuse potential and variable outcomes. Gabapentin has also been used off-label for kratom withdrawal symptoms such as restlessness resembling restless legs syndrome and anxiety, with no established standard dosage; limited evidence from case reports and studies on similar opioid-like withdrawals suggests potential benefit at divided doses of 1600-1800 mg/day, though use requires medical supervision owing to risks of dependence, side effects, and interactions, and self-medication is not recommended. Overall, while off-label prescribing has surged—exceeding approved uses in some reports—many applications lack robust, independent evidence, prompting calls for caution amid rising misuse concerns.

Evidence of Efficacy and Limitations

Gabapentin demonstrates efficacy as an adjunctive therapy for partial s in patients with , with clinical trials showing dose-dependent reductions in seizure frequency. Although starting doses may be as low as 600 mg/day, efficacy at such levels is limited, with studies recommending titration to higher doses for optimal benefit. In double-blind, -controlled studies involving adults with partial seizures, gabapentin at 1200 mg/day and 1800 mg/day reduced seizure frequency by approximately 20-30% compared to placebo, with effects observed across doses from 1800 mg/day to 3600 mg/day. Monotherapy trials in newly diagnosed partial further support its use, where 900 mg/day or 1800 mg/day achieved seizure freedom or significant reduction in 40-50% of patients over 12-24 weeks. However, as an add-on treatment for drug-resistant focal , a Cochrane review of trials up to 2021 found limited high-quality evidence, with only modest reductions in seizure frequency (around 25%) and reliance on older, smaller studies prone to bias. For (PHN), gabapentin provides moderate pain relief, with meta-analyses of randomized controlled trials indicating at least 30% pain reduction in 40-50% of patients versus 20-30% on , often within the first week of to 1800-3600 mg/day; efficacy at doses as low as 600 mg/day may be limited, with titration to higher doses recommended for optimal benefit. This efficacy is supported by FDA approval based on pivotal trials showing sustained improvements in pain scores and measures over 8 weeks. Comparative analyses suggest gabapentin is inferior to in onset speed and overall effect size for PHN, though it has a lower adverse event rate. Off-label applications, such as other chronic neuropathic pains (e.g., ), show inconsistent efficacy; a Cochrane review of 37 trials reported moderate benefit (≥30% pain relief) in about 52% of participants at ≥1200 mg/day versus 31% on , but only for central and PHN, with insufficient data for broader peripheral neuropathies and limited efficacy at lower doses like 600 mg/day. Evidence for psychiatric off-label uses like anxiety or is weak and limited, with mixed results overall; small studies suggest potential benefits for social anxiety, but evidence is weaker for generalized anxiety disorder (GAD), derived largely from small, uncontrolled studies lacking large-scale trials, alongside high responses and selective reporting in industry-sponsored trials. Key limitations include small-to-moderate effect sizes overshadowed by high responses in trials (often 20-30%), short trial durations (typically 8-12 weeks) lacking long-term data, and dose-response inconsistencies requiring to high levels (≥1800 mg/day) for benefit, which increases dropout rates due to side effects like in 20-30% of users. Industry influence has led to underreporting of negative outcomes in off-label trials, inflating perceived , while real-world effectiveness is hampered by pharmacokinetic variability and non-response in up to 50% of patients. Common alternatives for neuropathic pain (e.g., diabetic neuropathy, postherpetic neuralgia) include pregabalin (Lyrica), a similar anticonvulsant; duloxetine (Cymbalta), an SNRI antidepressant; and tricyclic antidepressants like amitriptyline or nortriptyline. Nonprescription options include topical capsaicin, acetaminophen, ibuprofen, and supplements like alpha-lipoic acid. Selection of alternatives depends on the condition and individual factors; consultation with a healthcare provider is advised. Gabapentin is not superior to alternatives like or tricyclics in head-to-head comparisons for many indications, and its benefits must be weighed against risks of misuse and dependence, particularly off-label.

Adverse Effects and Safety Concerns

Common Side Effects

The most common adverse reactions to gabapentin, observed in controlled clinical trials, primarily affect the and include and , which frequently lead to treatment discontinuation. In trials for among adults, occurred in 28% of patients receiving gabapentin (versus 7% on ), in 21% (versus 4%), and in 8% (versus 2%). In trials for patients over 12 years, affected 19%, 17%, 13%, and 11%. These effects exhibit dose dependence, with higher incidences reported at daily doses of 1800 mg or greater; for instance, reached 20.2% at lower doses but increased further at elevated levels, alongside (13.8%) and as the next most frequent. At low doses such as 600 mg/day, often used as a starting dose, the incidence of common side effects like dizziness and somnolence is lower than at standard therapeutic doses of 900-3600 mg/day, with generally good tolerability reported in initial therapy for conditions like postherpetic neuralgia. However, risks such as falls and altered mental status may increase at doses ≥600 mg/day in some populations, and dependence potential persists even at low levels. Other commonly reported reactions (1-10% incidence) encompass , , abnormal coordination, , asthenia, weight gain, blurred vision, and gastrointestinal effects such as dyspepsia (approximately 2% versus 1% placebo) and heartburn (which may be associated with acid reflux symptoms, though gastroesophageal reflux disease is not directly listed as a common side effect), often resolving with dose adjustment or discontinuation but contributing to impaired balance, gait disturbances, and cognitive slowing. In pediatric patients aged 3-12 years, viral infections (11%) and fever (10%) were also notable, though effects like remained prevalent at 8%.
Adverse ReactionApproximate Incidence (>10%)
Somnolence19-21%
17-28%
13%
11%
Fever11%

Serious Acute Risks

Serious acute risks associated with gabapentin include severe reactions, such as and , which can manifest as swelling of the face, lips, tongue, or throat, difficulty breathing, , , or itching, potentially leading to life-threatening outcomes requiring immediate medical intervention, as well as pancreatitis. Multiorgan hypersensitivity reactions, also known as drug reaction with eosinophilia and systemic symptoms (DRESS), may occur and present with fever, rash, and lymphadenopathy, among other symptoms. The U.S. Food and Drug Administration (FDA) prescribing information for Neurontin (gabapentin) warns of serious or life-threatening allergic reactions that may involve multi-organ effects, including liver dysfunction or blood cell abnormalities, with onset typically within days of initiation or dose increase. Gabapentin has numerous drug interactions, primarily with central nervous system (CNS) depressants such as opioids, benzodiazepines, alcohol, and morphine, as well as certain other medications like losartan and antacids (which can reduce gabapentin absorption). These interactions can increase risks of sedation, dizziness, respiratory depression, and potentially life-threatening breathing problems. Specifically, gabapentin and tramadol have a major drug interaction; combining them increases the risk of serious central nervous system depression, including respiratory depression, profound sedation, coma, and death. The combination should generally be avoided; if necessary, use with close monitoring, dose adjustments, and caution, especially in vulnerable patients (e.g., elderly or those with respiratory issues). The FDA has warned about serious respiratory depression when gabapentin is combined with CNS depressants. There is no evidence that low doses eliminate or significantly reduce these interaction risks; however, when combining with opioids or similar drugs, guidelines recommend starting gabapentin at the lowest effective dose and monitoring closely for side effects. Respiratory depression represents another critical acute hazard, especially with opioids or in patients with respiratory impairment, and particularly in patients with compromised respiratory function, such as those with (COPD), or when gabapentin is co-administered with opioids, depressants, or in overdose scenarios; caution is advised with concomitant use of CNS depressants or opioids due to additive effects increasing the risk of respiratory depression. The FDA issued a communication on December 19, 2019, highlighting reports of serious, life-threatening, and breathing difficulties, often presenting as slowed or , unresponsiveness, or , with heightened risk in elderly patients or those with . In gabapentinoid poisoning, symptoms may include lethargy progressing to agitation or , exacerbating mortality when combined with opioids. Acute overdose, whether intentional or accidental, can precipitate severe , including profound drowsiness, , , , , , , and in extreme cases, seizures, , or death, though gabapentin alone rarely causes fatality without polysubstance involvement. Abrupt discontinuation should be avoided due to the risk of precipitating seizures or status epilepticus. Symptoms typically emerge rapidly after ingestion of doses exceeding 49 grams, as documented in case reports, with supportive care like and as key interventions for elimination given its renal clearance. Dose adjustments are required in patients with renal insufficiency. Emergent psychiatric effects, such as acute , behavioral worsening, or severe mood changes including depression and irritability, have been observed soon after starting therapy or changing doses, with clinical trials indicating a elevation of approximately 1.8-fold compared to . The FDA has issued a black box warning for gabapentin and other antiepileptic drugs regarding an increased risk of suicidal thoughts or behavior, with pooled analyses of trials showing an absolute risk increase of about 1 in 500 patients; risks may be higher in individuals with a history of mood disorders, and symptoms may reverse upon discontinuation. These effects prompt FDA-mandated warnings for monitoring mood changes. If new or worsening mood changes occur—especially depression, agitation, or suicidal thoughts—patients should contact a healthcare professional or seek emergency help immediately (e.g., call 988 in the US for suicide prevention); a healthcare professional can assess specific risks and monitor accordingly. These risks underscore the need for prompt discontinuation and evaluation if severe symptoms arise, as is supported by temporal association in post-marketing surveillance rather than definitive mechanistic proof. Although not an opioid or benzodiazepine, gabapentin carries potential for dependence and withdrawal syndrome.

Long-Term Health Risks

Long-term use of gabapentin has raised concerns regarding cognitive decline and risk, particularly among patients with conditions. A published in July 2025 analyzed adults with and found that those receiving six or more prescriptions of gabapentin exhibited an 85% higher risk of or compared to non-users, with risks escalating in younger patients under 65 and those on higher cumulative doses. Similarly, a 2023 analysis reported elevated incidence in patients treated with gabapentin or , attributing potential mechanisms to effects like memory impairment from prolonged exposure. However, a study examining long-term gabapentin therapy for concluded no differential risk across dosage levels, age groups, or genders, suggesting variability in outcomes may depend on patient-specific factors such as comorbidities or concurrent medications. Chronic gabapentin administration may also promote neurodegenerative changes in the , as evidenced by preclinical data showing increased neuronal damage in adult models following prolonged exposure, potentially exacerbating conditions like or neuropathy over time. Cardiovascular risks appear heightened with extended use, including elevated incidences of , , and other adverse events, particularly in patients with preexisting renal or heart conditions; one 2022 linked gabapentin to such outcomes, recommending careful monitoring and dose adjustments. Additionally, Yale researchers in 2024 reported that even low-dose chronic exposure correlates with increased hospitalization rates across all ages, adjusted for comorbidities, underscoring broader systemic vulnerabilities. Respiratory depression remains a persistent concern in long-term users, especially when combined with opioids or other CNS depressants, with FDA warnings from 2020 highlighting fatal risks from cumulative effects like , though primarily acute, these can manifest chronically in vulnerable populations such as the elderly or those with . Clinical reviews caution against indefinite high-dose therapy for due to net harm outweighing benefits in some cases, advocating periodic reassessment to mitigate these accumulating risks.

Dependence, Misuse, and Withdrawal

Potential for Dependence

Gabapentin carries a potential for , particularly after prolonged use at therapeutic or supratherapeutic doses, as documented in case reports and clinical observations of withdrawal upon abrupt cessation. Dependence manifests through tolerance, where patients escalate doses beyond prescriptions, and withdrawal symptoms including anxiety, agitation, , , diaphoresis, , and , with onset typically within 12 hours and duration up to 10 days. In severe instances, withdrawal has precipitated , disorientation, hallucinations, and , often requiring management with benzodiazepines or reinstatement of gabapentin. Evidence indicates dependence can emerge even at low doses, such as 400 mg daily for in some patients, challenging earlier assumptions of negligible risk at standard therapeutic levels (900–3600 mg/day). Preclinical studies in mice demonstrate gabapentin-induced at high doses (300 mg/kg), linked to dopamine release in the shell via D1 receptor activation, suggesting a neurobiological basis for drug-seeking behavior akin to other dependence-forming agents. Clinical pharmacovigilance data, including reports to the FDA's Adverse Event Reporting System (2012–2016) and (2004–2015), corroborate dependence signals, with thousands of cases involving , tolerance, and withdrawal among recipients. Risk of dependence is markedly elevated in individuals with a history of substance use disorders, particularly misuse, where co-administration potentiates euphoric effects and escalates liability; prevalence of gabapentin misuse reaches 15–22% in this group compared to 1.1% in the general population. Among prescription holders, misuse rates range from 40–65%, often driven by for withdrawal from other substances or enhancement of effects. Systematic reviews highlight limited intrinsic rewarding properties relative to classical addictive drugs, attributing higher dependence potential primarily to vulnerable populations rather than broad addictiveness, though accumulating has prompted regulatory scrutiny, including FDA-mandated clinical trials on potential since 2019.

Patterns of Misuse and Recreational Use

Gabapentin is commonly misused at high doses to produce euphoric, , and effects, with users describing relaxation, improved sociability, a marijuana-like high, and occasionally cocaine-like stimulation. Recreational doses typically range from 600 to 4,800 mg when taken orally alone, far exceeding standard therapeutic levels of 900–3,600 mg daily, though some reports involve snorting capsule contents to intensify onset. These effects stem from gabapentin's enhancement of transmission and potential modulation of release, though empirical data on mechanisms remain limited to preclinical models. Misuse prevalence in the general population is low, estimated at 1.1% lifetime use in a 2013 UK survey of individuals aged 16–59, but escalates markedly in high-risk groups: 40–65% among prescription holders and 15–22% among those with opioid use disorder per US and UK studies. In the US, nonmedical use has risen sharply, with recreational reports increasing 2,950% in Appalachian Kentucky from 2008 to 2015 and 165% year-over-year in one regional sample of 503 adults where 15% admitted recent nonmedical use. Among new US prescribers, approximately 6% of gabapentin initiators and 10% of pregabalin initiators showed misuse signals within two years. Patterns frequently involve polydrug use, particularly to potentiate opioids like or illicit , amplifying and while heightening overdose risk through respiratory depression; data show co-occurrence with opioids in 43% and benzodiazepines in 44% of misuse-related cases. Diversion sources include legitimate prescriptions (52–63% of cases), sharing from family or acquaintances, and online purchases, with street prices of $1–7 per capsule. for pain, anxiety, or substance withdrawal accounts for some instances, but recreational "getting high" predominates, especially in populations with existing substance use disorders. Gabapentin's non-federal scheduling by the DEA facilitates access, though several states classify it as Schedule V due to abuse trends.

Withdrawal Symptoms and Management

Abrupt discontinuation of gabapentin should be avoided due to the serious risk of withdrawal seizures and status epilepticus, particularly after prolonged high-dose therapy, which may require immediate medical management; gradual tapering is recommended instead. This can lead to a withdrawal syndrome resembling that of other agents. Symptoms reported in case studies and reviews include agitation, anxiety, , diaphoresis, chills, , , anorexia, abdominal or somatic , , , , and altered mental status such as or disorientation. Patient-reported experiences in online communities, such as Reddit's r/gabapentin and r/ChronicPain, commonly describe severe anxiety, insomnia, rebound pain, restlessness, sweating, and discomfort, often exacerbated by abrupt cessation or high doses, with discussions highlighting tapering difficulties, fears of cold turkey discontinuation, and varied severity that challenges perceptions of mild withdrawal. Onset of withdrawal typically ranges from 12 hours to 7 days post-cessation, with symptoms potentially persisting or peaking over 10 days even after a one-week taper. Risk factors encompass daily doses above 3000 mg, treatment duration exceeding months, elderly age, psychiatric comorbidities, and prior substance use history. Management emphasizes gradual tapering to minimize symptom emergence, as abrupt or rapid reduction—even over one week—can provoke withdrawal in vulnerable patients. Recommended protocols include dose decrements of 10-25% biweekly, extending over weeks to months, with adjustments for renal function and individual response; in one case, restarting at 400 mg daily followed by to 1400 mg resolved symptoms within 3 days before slower discontinuation. Supportive measures involve vital sign monitoring, hydration, and symptomatic relief, though no standardized pharmacotherapies exist due to reliance on case-based evidence rather than controlled trials. Patients with dependence risk should undergo supervised tapering to avoid rebound exacerbation of underlying conditions like or seizures.

Pharmacology

Pharmacodynamics

Gabapentin, a , primarily acts by high-affinity binding to the α₂δ-1 and, to a lesser extent, α₂δ-2 auxiliary subunits of voltage-gated calcium channels (VGCCs), particularly high-voltage-activated N- and P/Q-type channels. This interaction occurs at an exofacial on the subunits, with a (K_d) of approximately 59 nM for α₂δ-1 and 153 nM for α₂δ-2, inhibiting the forward trafficking of these subunits to presynaptic membranes and reducing calcium influx during . Consequently, gabapentin decreases the evoked release of excitatory neurotransmitters, including glutamate, norepinephrine, , and , from central and peripheral s, thereby attenuating neuronal excitability. Although structurally analogous to γ-aminobutyric acid (GABA), gabapentin exhibits no direct at GABA_A or GABA_B receptors, nor does it inhibit GABA or uptake mechanisms. and studies demonstrate indirect modulation of transmission, with gabapentin increasing brain GABA concentrations—up to 30-50% in rodents and humans—potentially via enhanced glutamic acid decarboxylase activity or reduced excitatory drive, though the precise pathway remains incompletely elucidated. Electrophysiological data further indicate minor inhibitory effects on voltage-gated sodium channels and potential suppression of ascending nociceptive signaling in the , contributing to its and profiles. Preclinical models reveal that α₂δ-1 binding disrupts thrombospondin-mediated , limiting excitatory synapse formation in pathological states like or , which may underlie gabapentin's therapeutic delay of onset. These actions collectively reduce , , and seizure propagation without broad CNS depression, distinguishing gabapentin from traditional GABA mimetics or blockers. However, the relative contributions of modulation versus other downstream effects, such as monoamine release inhibition, vary by tissue and dose, with human pharmacodynamic responses inferred largely from animal data and binding assays.

Pharmacokinetics

Gabapentin exhibits nonlinear, dose-dependent pharmacokinetics due to via the L-amino acid transporter (LAT1) in the proximal . Concurrent administration of magnesium-containing substances, such as antacids or supplements, can reduce gabapentin absorption and bioavailability; doses should be separated by at least 2 hours. Oral decreases with increasing dose, ranging from approximately 60% at 300 mg to 33-35% at 1600 mg, with peak plasma concentrations achieved 2-3 hours post-administration. Following absorption, gabapentin distributes widely with a of about 58 L in adults, and it demonstrates low of less than 3%. The drug crosses the blood-brain barrier, achieving concentrations roughly 7-35% of plasma levels, consistent with its effects. Gabapentin undergoes negligible hepatic , with less than 1% of an administered dose converted to metabolites in humans; the remainder is excreted unchanged. Elimination occurs primarily via renal excretion through glomerular filtration and minor tubular secretion, with an elimination of 5-7 hours that remains constant regardless of dose or repeated administration. In patients with reduced clearance, clearance proportionally decreases, necessitating dose adjustments to avoid accumulation. Steady-state plasma concentrations are predictable from single-dose data, as are unaltered by multiple dosing.

Preclinical Studies

Gabapentin, chemically 1-(aminomethyl)cyclohexaneacetic acid, was first synthesized in 1975 by chemists at (a of Warner-Lambert) as part of a systematic search for GABA mimetics capable of crossing the blood-brain barrier to treat . Initial preclinical screening focused on its potential in models, where it exhibited efficacy against electrically and chemically induced seizures without direct at GABA_A or GABA_B receptors, distinguishing it from classical agents. In mice, gabapentin protected against maximal electroshock (MES)-induced tonic hindlimb extension at doses of 50-200 mg/kg intraperitoneally, with ED50 values around 80-100 mg/kg, and delayed the onset of pentylenetetrazol (PTZ)-induced clonic convulsions, indicating broad-spectrum activity in generalized seizure models. Similar effects were observed in rats, including suppression of amygdala-kindled seizures in immature animals at non-sedating doses (10-50 mg/kg), without significant motor impairment. Audiogenic seizure models in genetically prone mice further confirmed its ability to raise seizure thresholds, supporting its progression to clinical trials for partial seizures. Mechanistic studies in preclinical models revealed gabapentin's binding to the α2δ-1 subunit of voltage-gated calcium channels (VGCCs) in neuronal tissues, with high-affinity saturation (Kd ≈ 59 nM in membranes), leading to reduced calcium influx and decreased excitatory release such as glutamate. This interaction correlated with potency across species, as other α2δ ligands like showed analogous effects in models. Pharmacokinetic analyses in rats demonstrated a delay in concentration peaks relative to plasma levels, explaining the temporal mismatch with peak effects and emphasizing via the L-amino acid system. Preclinical toxicology in and dogs indicated a favorable profile, with oral LD50 exceeding 8000 mg/kg in mice and no evidence of or teratogenicity at therapeutic exposures; however, high doses caused and , mirroring later clinical observations. Extended studies also explored potential, showing antihyperalgesic effects in rodent models of inflammatory and via VGCC modulation, though remained the primary indication for development.

Chemistry

Chemical Structure and Properties

Gabapentin, with the IUPAC name 2-[1-(aminomethyl)cyclohexyl]acetic acid, consists of a ring bearing an aminomethyl substituent (-CH₂NH₂) and a carboxymethyl group (-CH₂COOH) at the same carbon atom (position 1). This configuration positions the amino and functionalities in a manner analogous to the gamma-amino acid structure of GABA, though the rigid cyclohexyl backbone replaces GABA's flexible chain, altering conformational flexibility and preventing direct mimicry of GABA's binding. The molecule's zwitterionic form predominates at physiological due to its pKa values of 3.7 for the and 10.7 for the group. The molecular formula of gabapentin is C₉H₁₇NO₂, and its molecular weight is 171.24 g/mol. It manifests as a white to off-white crystalline solid with a ranging from 165 to 167 °C. Gabapentin exhibits high solubility, exceeding 10% at 7.4, and is freely soluble in both acidic and basic aqueous solutions, consistent with its amphoteric nature. Its hydrophilicity is evidenced by a logP value of approximately -1.3, indicating low and limited passive membrane permeation. No distinct is reported, as the compound likely decomposes prior to boiling under standard conditions. The occurs at 7.14, further underscoring its zwitterionic properties in neutral environments.

Synthesis and Manufacturing

Gabapentin, chemically 1-(aminomethyl)cyclohexylacetic acid, is primarily synthesized industrially through routes involving the Hofmann or Curtius rearrangement of key intermediates derived from 1,1-cyclohexanediacetic acid. One established process begins with the formation of 1,1-cyclohexanediacetic acid monoamide from 1,1-cyclohexanediacetic acid anhydride reacted with an ammonia source, such as ammonium carbonate or an ammonia-isopropanol solution, at 0–10°C in solvents like toluene or isopropanol. The monoamide undergoes Hofmann rearrangement using sodium hypobromite at –5 to –10°C followed by heating to 55°C, yielding gabapentin hydrochloride after acidification with HCl; this step achieves low levels of the impurity gabalactam (<7%). The hydrochloride is then extracted with ethanol, neutralized with triethylamine, and crystallized as Form II gabapentin from a water-acetone mixture (1:4 to 1:5 ratio), providing high purity without inorganic salts or ion exchange. Alternative syntheses employ the Guareschi-Imido reaction, starting from cyclohexanone and ethyl cyanoacetate in the presence of ammonia to form a Guareschi salt, which is hydrolyzed and decarboxylated to 1,1-cyclohexanediacetic acid. The diacid is converted to its anhydride with acetic anhydride, then to a half-ester with methanol, followed by Curtius-type rearrangement to an isocyanate intermediate, and final hydrolysis with HCl in tetrahydrofuran-water, yielding gabapentin at 98% efficiency after anion exchange for salt removal. Other variants, such as those using dilute sulfuric acid (50–70%) for hydrolyzing dicarbonitrile intermediates at 90–110°C or alkaline hydrolysis of diimides at reflux, optimize yields to ~80% and reduce environmental hazards by avoiding concentrated acids. In manufacturing, raw materials including cyclohexanone derivatives, ethyl cyanoacetate or chloroacetate, sodium hydroxide, and ammonia undergo acylation, hydrolysis, and rearrangement under good manufacturing practice (GMP) conditions. Intermediates like the monoamide or diimide are purified via recrystallization to remove impurities, followed by Hofmann or analogous reactions to introduce the aminomethyl group. Final gabapentin is isolated by crystallization, often as the free base or monohydrate dehydrated with methanol and activated carbon treatment, ensuring >99% purity verified by and per FDA and EMA standards. Industrial innovations, such as continuous microreaction systems, enhance heat and for scalable production while minimizing costs, with raw materials comprising 40–60% of expenses. At least five synthetic routes have been developed for generic production, prioritizing efficiency and impurity control.

History and Development

Discovery and Preclinical Phase

Gabapentin, chemically known as 1-(aminomethyl)cyclohexaneacetic acid, was synthesized in 1974 by Gerhard Satzinger and colleagues at Goedecke AG, the German research division of Parke-Davis, as part of a program to develop centrally active analogs of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). The molecule was designed to mimic GABA's structure while incorporating a lipophilic cyclohexane ring to facilitate penetration of the blood-brain barrier, addressing the limitation that endogenous GABA does not readily cross this barrier. This innovation stemmed from first-principles efforts to enhance GABAergic neurotransmission for potential antiepileptic applications, building on the known anticonvulsant properties of GABA but overcoming its poor pharmacokinetics. The compound was first patented in under DE 24 60 891 in 1976, with Satzinger listed as a primary inventor, followed by corresponding U.S. 4,024,175 issued in 1977 to Warner-Lambert (Parke-Davis's parent company). Initial evaluations confirmed gabapentin's structural similarity to GABA but revealed it did not directly activate GABA_A or GABA_B receptors, prompting further investigation into alternative mechanisms. Preclinical development advanced through animal toxicology studies conducted at Goedecke from approximately 1980 to 1982, which established safety profiles in rodents and other species at doses relevant to anticonvulsant efficacy. Efficacy testing in rodent seizure models, including maximal electroshock and pentylenetetrazol-induced convulsions, demonstrated gabapentin's ability to suppress seizures at oral doses of 10–100 mg/kg, comparable to established antiepileptics like phenytoin, without significant sedative side effects at therapeutic levels. These findings supported its progression, though the precise mechanism—later identified as binding to the α2δ subunit of voltage-gated calcium channels—emerged from subsequent binding assays rather than initial GABA-focused hypotheses. Additional preclinical work in the mid-1980s explored gabapentin's effects in models of , such as ligation in rats, where it reduced and via intraperitoneal administration, foreshadowing off-label applications despite its primary focus. No rewarding or dependence-like behaviors were observed in standard animal paradigms, aligning with its non-scheduled status initially. These data collectively validated gabapentin's tolerability and preliminary therapeutic potential, paving the way for human trials starting in 1987.

Clinical Trials and Regulatory Approval

Gabapentin's initial regulatory approval stemmed from clinical trials demonstrating its as adjunctive therapy for partial s in adults with . The U.S. (FDA) granted approval on December 30, 1993, based on data from three multicenter, randomized, double-blind, -controlled trials involving a total of 705 patients with refractory partial s who were already on one to three concomitant antiepileptic drugs. In these studies, gabapentin at doses ranging from 1,800 mg/day to 3,600 mg/day reduced frequency by approximately 20% compared to , with comparable across the dose range and a favorable tolerability profile relative to higher doses. The trials established gabapentin's role in reducing the frequency of complex partial s and secondarily generalized tonic-clonic s, though it showed limited as monotherapy. In , gabapentin received marketing authorization shortly thereafter, with availability in the region beginning in May 1993 for similar epilepsy indications, following national approvals aligned with emerging data from the same foundational trials. These early studies, conducted primarily by (later acquired by ), emphasized gabapentin's mechanism as a gamma-aminobutyric acid (GABA) analog, though its antiseizure effects were not solely attributable to GABA mimicry, prompting further pharmacokinetic and pharmacodynamic scrutiny. Subsequent approval for (PHN) in 2002 expanded gabapentin's indications, supported by two dedicated randomized, double-blind, -controlled trials enrolling 563 patients, of whom 336 received gabapentin titrated to 1,800–3,600 mg/day. These trials, conducted in patients with pain persisting at least three months after resolution, demonstrated statistically significant reductions in mean pain scores (by 2.5–3 points on a 10-point scale versus ) and improvements in secondary outcomes like sleep interference and measures. The FDA's supplemental approval on May 24, 2002, highlighted gabapentin's rapid onset of analgesia (within one week) and overall safety, with common adverse events including and , though dropout rates due to side effects remained low at around 10–15%. These PHN trials built on data but faced criticism in later analyses for selective outcome reporting in some industry-sponsored studies, underscoring the need for independent verification of efficacy claims.

Post-Approval Surveillance and Updates

Following its approval by the U.S. (FDA) in 1993 for and supplemental approval in 2002 for , gabapentin underwent ongoing post-marketing surveillance through systems like the FDA Reporting (FAERS), which identified signals of serious adverse events including respiratory depression, particularly when co-prescribed with opioids or depressants. In December 2019, the FDA issued a Drug Safety Communication requiring label updates for gabapentin and to warn of potentially fatal respiratory depression in patients with compromised respiratory function, such as those with , or when combined with opioids; this followed analysis of post-marketing reports and clinical data showing disproportionate risks in vulnerable populations. Surveillance also revealed emerging abuse potential, with post-marketing data indicating gabapentin's misuse for euphoric effects, often alongside opioids or to enhance their high, contributing to overdose risks amid the U.S. opioid epidemic. Although not federally scheduled, states including Kentucky (2017), Tennessee (2018), and Michigan (2018) reclassified gabapentin as a Schedule V controlled substance based on surveillance of prescribing patterns, emergency department visits, and diversion reports, aiming to mandate reporting and limit access without federal action. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) issued a 2017 alert on rare severe respiratory depression cases independent of opioids, prompting label revisions. Additional updates addressed reactions and withdrawal; post-marketing reports documented discontinuation symptoms like anxiety and after high-dose use, leading to label inclusions for gradual tapering. In 2024, FAERS signals prompted warnings for (SCARs), including Stevens-Johnson syndrome, with label updates emphasizing early discontinuation upon rash onset. Surveillance continues to monitor off-label prescribing trends, which surged post-approval for unapproved indications like and anxiety, correlating with higher adverse event rates in real-world data.

Regulatory Status

United States

Gabapentin received initial approval from the U.S. (FDA) on December 30, 1993, as Neurontin for use as adjunctive therapy in the treatment of partial seizures in adults with . The FDA approved an additional indication for the management of in adults on May 31, 2002. Gabapentin has been available in generic form in the since 2004, leading to widespread prescribing beyond its labeled uses. Federally, gabapentin is not classified as a under the by the (DEA), reflecting its originally low perceived abuse potential when approved. However, rising reports of misuse, diversion, and enhancement of effects prompted state-level actions; as of 2024, at least 15 states, including (effective July 1, 2017), (July 1, 2018), (July 2018), (2020), and , have scheduled gabapentin as a V , subjecting it to monitoring, prescription limits, and reporting requirements similar to other drugs with limited abuse potential. These measures aim to curb nonmedical use amid the , though federal scheduling has not occurred despite DEA evaluations. In response to post-marketing surveillance data, the FDA issued a safety communication on December 19, 2019, requiring updated labeling for gabapentin products to warn of serious, potentially fatal respiratory depression, particularly in patients with compromised respiratory function, advanced age, or concomitant use of opioids or depressants. This action followed reports of adverse events, including deaths, and built on prior class-wide warnings for antiepileptic drugs regarding and behavior, mandated since 2008. No further federal regulatory changes to approval status have been enacted as of October 2025, though ongoing continues to track misuse trends.

United Kingdom

In the , gabapentin is authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) as a prescription-only for the treatment of (partial seizures with or without secondary generalisation) in patients aged six years and older, and for peripheral in adults. Following concerns over misuse, dependence, and related fatalities—evidenced by rising hospital admissions and deaths linked to recreational use—gabapentin was reclassified as a Class C under the , effective 1 April 2019. This change, mirrored for , aimed to curb diversion and non-medical use while maintaining access for legitimate patients, as supported by data from the National Programme on Deaths showing gabapentin involvement in 96 deaths in 2017. Under the Misuse of Drugs Regulations 2001, gabapentin is now a Schedule 3 controlled (without safe custody requirements), mandating specific prescribing protocols to prevent abuse. Prescriptions must be handwritten or electronically generated with equivalent security, include the patient's name and address, prescriber's details, date, signature, drug name, form, strength, quantity, and dosage instructions; they are valid for 28 days from the date issued, with no emergency supply permitted by pharmacists. Pharmacists must record all Schedule 3 prescriptions in a dedicated register, retained for two years, and destruction of stock requires witnessing, though safe storage is not mandated. Unlawful possession or supply without prescription carries penalties up to 14 years imprisonment under Class C provisions. Gabapentin is not subject to specified blood concentration limits under UK drug driving laws pursuant to the Road Traffic Act 1988 (as amended). It is permissible to drive while taking gabapentin as prescribed provided it does not impair driving ability. However, common side effects including drowsiness, dizziness, and impaired coordination can render driving unsafe and potentially illegal under section 4 of the Road Traffic Act 1988 if fitness to drive is compromised. Driving while unfit due to any drug, whether prescribed or otherwise, constitutes an offence subject to prosecution, including penalties such as fines, driving bans, or imprisonment. Patients are advised to consult their healthcare provider or pharmacist regarding individual risks and to refrain from driving if affected. Gabapentin's classification as a Class C controlled drug under the Misuse of Drugs Act 1971 does not entail automatic driving prohibitions beyond general impairment rules. Post-reclassification monitoring by the Advisory Council on the Misuse of Drugs and MHRA has confirmed ongoing risks, including polysubstance interactions contributing to overdoses, prompting guidance for cautious initiation, dose titration, and regular reviews to minimise dependence. As of 2025, no further reclassifications have occurred, with authorisation reaffirming benefits outweigh risks when used as directed.

Other Countries and Veterinary Regulations

In Canada, gabapentin is approved by for the treatment of and , with multiple generic formulations authorized since the early 2010s, but it is not classified as a , though its use is monitored due to risks of misuse and interaction with opioids. In , the (TGA) lists gabapentin as a Schedule 4 prescription-only medicine, approved since 1994 for refractory partial and , with enhanced warnings issued in 2021 regarding abuse potential and dependence; it is subsidized under the for limited indications but tracked in real-time monitoring systems like SafeScript in some states since July 2023. Within the , gabapentin is authorized nationally or via mutual recognition procedures for and peripheral , following a 2001 EMA referral that harmonized indications across member states, though it lacks centralized scheduling as a and consumption varies widely by country without uniform misuse controls. Gabapentin is not specifically approved for veterinary use by regulatory bodies such as the FDA, EMA, or equivalents in and , but veterinarians legally prescribe it off-label under provisions like the U.S. Animal Medicinal Drug Use Clarification Act for managing chronic (recommended in veterinary guidelines as an adjunct in multi-modal pain management for dogs, including senior dogs, for post-operative pain such as after cranial cruciate ligament (ACL) surgery and neuropathic pain potentially associated with stroke or other neurologic conditions; particularly useful in seniors due to lower risk of GI/renal side effects compared to NSAIDs alone, with multi-modal approaches combining gabapentin with NSAIDs, opioids, amantadine, and other agents for better pain control and reduced opioid use; typical dosage for chronic/neuropathic pain in dogs: 10-20 mg/kg PO q8-12h, starting lower in seniors (e.g., 5-10 mg/kg) and titrating based on response and renal/hepatic function; evidence supports its use post-orthopedic surgery and for central/neuropathic pain, including as an adjunct to NSAIDs at 10–30 mg/kg, 2–3 times daily, targeting neuropathic components in dogs with chronic osteoarthritis; sedating effects can provide additional benefit but may necessitate dose adjustments, with studies showing improved weight-bearing and reduced lameness; common adverse effects in dogs include sedation (most frequent), ataxia (hindlimb weakness or uncoordinated gait), and occasional gastrointestinal signs (vomiting, diarrhea) at higher doses; these are generally mild and transient), seizures, and anxiety in dogs and cats. In jurisdictions like , U.S. veterinarians must report dispensations exceeding 48-hour supplies to controlled substance monitoring systems since March 2024, reflecting emerging scrutiny over diversion risks, while international veterinary practices mirror this off-label application without dedicated approvals or widespread reporting mandates documented as of 2025.

Marketing Controversies and Societal Impact

Off-Label Promotion and Pharmaceutical Practices

Warner-Lambert, a subsidiary of , engaged in a systematic campaign to promote gabapentin (marketed as Neurontin) for unapproved off-label uses, including psychiatric disorders such as and anxiety, as well as conditions like migraine prophylaxis and , despite FDA approval limited to adjunct therapy and . This promotion involved paying medical education companies to develop supposedly independent programs that emphasized off-label benefits, funding ghostwritten articles in medical journals, and providing financial incentives to physicians to prescribe and speak favorably about the drug for non-indicated purposes. Internal documents revealed a deliberate strategy to "turn Neurontin into a blockbuster" by targeting physicians and expanding indications beyond evidence-based support, resulting in off-label prescriptions accounting for up to 90% of sales by the early 2000s. The U.S. Department of investigated these practices following a whistleblower filed by former medical liaison David Franklin in 1996, who alleged fraudulent tactics including the fabrication of and suppression of negative results. On May 13, 2004, Warner-Lambert pleaded guilty to two felony counts of violating the Food, Drug, and Cosmetic Act through misbranding Neurontin with intent to defraud or mislead, agreeing to pay a $430 million settlement—the largest healthcare settlement at the time—covering criminal fines, civil liabilities, and restitution for false claims submitted to government programs like . , having acquired Warner-Lambert in 2000, assumed responsibility for these actions despite not being directly charged in the plea. Subsequent civil litigation reinforced accountability for off-label promotion. In March 2010, a federal jury in Boston found Pfizer liable under the Racketeer Influenced and Corrupt Organizations Act for orchestrating a scheme to promote unapproved uses through paid physician "consultants" and manipulated clinical data, initially awarding $142 million in damages to Kaiser Permanente, though this was later reduced on appeal. Additional settlements followed, including $190 million in 2014 to direct purchasers and $325 million to third-party payors for antitrust and fraudulent marketing claims related to suppressing generic competition while expanding off-label sales. These cases highlighted how industry-sponsored trials selectively reported positive outcomes for off-label indications, undermining evidence validity and contributing to widespread adoption despite limited empirical support for efficacy in areas like neuropathic pain beyond FDA-approved contexts. Post-settlement analyses indicated that off-label promotion drove a surge in gabapentin prescribing, with U.S. prescriptions rising from 1.6 million in to over 20 million annually by the mid-2000s, but enforcement actions correlated with a decline in both off-label and on-label use, suggesting deterrence from aggressive marketing rather than shifts in clinical need. Specifically for bipolar disorder, gabapentin prescriptions peaked around 2002 but dropped sharply after the 2004 settlement halted misleading off-label promotion, combined with randomized controlled trials from the early 2000s showing lack of efficacy versus placebo, leading to wider recognition of weak evidence for mood disorders; a Florida Medicaid analysis documented this trend, with prescriptions declining by approximately 45% post-2004 amid policy changes influenced by the settlement. Critics, including FDA officials, noted that such practices prioritized —Neurontin generated $2.7 billion in peak sales—over rigorous and data, fostering dependency on pharmaceuticals with incomplete risk profiles, including potential for and withdrawal issues not fully disclosed during promotion. While off-label prescribing remains legal for physicians based on individual judgment, the Neurontin scandals underscored systemic incentives in pharmaceutical practices to exploit regulatory gaps, prompting calls for stricter oversight of industry influence on and research. In 2004, Warner-Lambert, a subsidiary, pleaded guilty to criminal charges of illegally promoting gabapentin (marketed as Neurontin) for off-label uses including psychiatric disorders, migraines, and not approved by the FDA, agreeing to pay $430 million in fines and penalties to resolve federal and state healthcare liabilities.00792-6/fulltext) This settlement stemmed from evidence that the company paid physicians to prescribe the drug off-label and suppressed negative trial data, contributing to prescriptions exceeding FDA-approved indications by over 80% in some periods. The off-label marketing practices escalated into broader litigation, culminating in a 2009 settlement where paid $2.3 billion—the largest healthcare fraud settlement in U.S. history at the time—to resolve civil and criminal allegations involving multiple drugs, including gabapentin promoted for unapproved uses such as and hot flashes. Internal documents revealed during the cases showed 's strategies included funding "educational" grants to doctors, ghostwriting studies, and influencing guidelines to expand indications, despite limited for many off-label applications. Subsequent antitrust class-action suits addressed alleged monopolistic tactics to delay generic competition, with Pfizer settling for $325 million in 2014 to compensate direct purchasers who claimed inflated prices due to suppressed generic entry for gabapentin capsules and tablets. In 2013, a federal appeals court upheld a $142 million verdict against for reimbursing healthcare programs for off-label gabapentin prescriptions induced by fraudulent marketing. These cases highlighted systemic issues in pharmaceutical promotion but did not result in , as gabapentin remained available with ongoing post-marketing surveillance for misuse and dependency risks. No major class-action settlements have emerged specifically for or severe side effects like respiratory depression, though regulatory warnings have increased since 2019 regarding abuse potential when combined with opioids. Gabapentin prescriptions in the United States rose substantially from 79.5 per 1,000 persons in 2010 to 177.6 per 1,000 persons in 2024, reflecting a more than twofold increase in dispensing rates. The absolute number of prescriptions grew from 24,186,175 in 2010 to 58,868,142 in 2024, positioning gabapentin as the fifth most prescribed medication in community pharmacies by 2024. This surge aligns with broader trends in gabapentinoid use, which tripled from 2002 to 2015, driven primarily by off-label applications such as neuropathic and musculoskeletal pain management, restless legs syndrome, anxiety, and headache. Approximately 95% of gabapentin prescriptions in recent U.S. analyses have been for off-label indications, often lacking robust evidence of efficacy beyond approved uses for epilepsy and postherpetic neuralgia. Concurrent prescribing with opioids also escalated, with opioid-gabapentin co-prescriptions increasing from 1.9% of opioid analgesic claims in 2006 to higher proportions by 2018, amplifying risks of adverse outcomes. Public health concerns have intensified due to rising misuse, , and diversion of gabapentin, particularly among individuals with seeking enhanced or withdrawal mitigation. Intentional misuse or accounted for approximately 10% of gabapentin exposures reported to U.S. poison centers in recent data, with gabapentin-involved overdoses frequently co-occurring with opioids, benzodiazepines, or alcohol, leading to respiratory depression and fatalities. Gabapentin detections in overdose deaths climbed steadily, with intentional -related exposures rising 104% from 2013 to 2017 in select surveillance systems, and patterns persisting into later years amid the opioid crisis. Dependence potential, including withdrawal symptoms like anxiety and , has been documented, though gabapentin's low mortality in isolation contrasts with synergistic lethality when combined with depressants. Regulatory responses have aimed to curb these trends, with 12 U.S. states classifying gabapentin as a Schedule V by 2025, alongside seven implementing monitoring program requirements, resulting in reduced days supplied per prescription in affected areas. Such measures, including mandatory reporting in systems like North Carolina's Controlled Substances Reporting System effective March 1, 2024, correlate with modest declines in prescribing volume, though national trends continued upward through 2024. These developments underscore the tension between gabapentin's utility in legitimate and its contribution to polysubstance overdose risks, prompting calls for enhanced prescriber screening for substance use history and monitoring for diversion.

Cost and Availability

Gabapentin (generic) without insurance typically costs $100+ for a 90-day supply at retail prices, but using a GoodRx coupon reduces it significantly—often to $5–$20 depending on dosage and quantity. Examples include $5.43 for 90 capsules of 300mg or $18.77 for 90 tablets of 600mg (prices vary by location, pharmacy, and date; GoodRx provides discounts for cash-paying customers).

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK493228/
  2. https://pubchem.ncbi.nlm.nih.gov/compound/Gabapentin
  3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020235s064_020882s047_021129s046lbl.pdf
  4. https://pubmed.ncbi.nlm.nih.gov/9686247/
  5. https://go.drugbank.com/drugs/DB00996
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC5573873/
  7. https://onlinelibrary.wiley.com/doi/abs/10.1111/add.13324
  8. https://www.sciencedirect.com/science/article/pii/S0955395924002895
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC6153543/
  10. https://www.drugs.com/gabapentin.html
  11. https://psychiatryonline.org/doi/10.1176/appi.ps.202000338
  12. https://www.nejm.org/doi/full/10.1056/NEJMsa0906126
  13. https://www.sciencedirect.com/science/article/pii/S2542454822000789
  14. https://www.jwatch.org/na48857/2019/04/02/markedly-increased-label-use-gabapentinoid-drugs-pain
  15. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2728959
  16. https://www.thecarlatreport.com/articles/3628-an-off-label-guide-to-gabapentin
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC3619699/
  18. https://pubmed.ncbi.nlm.nih.gov/21869694/
  19. https://www.jmcp.org/doi/10.18553/jmcp.2003.9.6.559
  20. https://www.aafp.org/pubs/afp/issues/2019/1201/p672.html
  21. https://pubmed.ncbi.nlm.nih.gov/16884455/
  22. https://www.neurology.org/doi/abs/10.1212/wnl.51.5.1282
  23. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001415.pub4/full
  24. https://pubmed.ncbi.nlm.nih.gov/24257149/
  25. https://pubmed.ncbi.nlm.nih.gov/36334235/
  26. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007938.pub4/full
  27. https://pubmed.ncbi.nlm.nih.gov/26835178/
  28. https://pubmed.ncbi.nlm.nih.gov/10440462/
  29. https://www.mayoclinic.org/diseases-conditions/peripheral-neuropathy/diagnosis-treatment/drc-20352067
  30. https://www.webmd.com/pain-management/nonprescription-treatments-nerve-pain
  31. https://link.springer.com/article/10.1007/s11606-023-08418-7
  32. https://pubmed.ncbi.nlm.nih.gov/15561647/
  33. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540277/
  34. https://www.drugs.com/sfx/gabapentin-side-effects.html
  35. https://medlineplus.gov/druginfo/meds/a694007.html
  36. https://www.mayoclinic.org/drugs-supplements/gabapentin-oral-route/description/drg-20064011
  37. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020235s068%2C020882s049%2C021129s049lbl.pdf
  38. https://www.drugs.com/drug-interactions/gabapentin-with-tramadol-1147-0-2221-0.html
  39. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin
  40. https://www.fda.gov/safety/medical-product-safety-information/neurontin-gralise-horizant-gabapentin-and-lyrica-lyrica-cr-pregabalin-drug-safety-communication
  41. https://www.uptodate.com/contents/gabapentinoid-poisoning-and-withdrawal
  42. https://www.poison.org/articles/neurontin-gabapentin
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC6692987/
  44. https://greenhousetreatment.com/gabapentin/overdose-dangers/
  45. https://www.therecoveryvillage.com/gabapentin-addiction/overdose/
  46. https://www.medicalnewstoday.com/articles/gabapentin-users-may-face-85-higher-risk-of-cognitive-impairment
  47. https://www.medpagetoday.com/neurology/painmanagement/116456
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC10266423/
  49. https://www.sciencedirect.com/science/article/abs/pii/S0165032724007493
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC4117164/
  51. https://pubmed.ncbi.nlm.nih.gov/36050764/
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC10706228/
  53. https://medicine.yale.edu/news-article/yale-va-researchers-study-side-effects-of-gabapentin/
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC10092611/
  55. https://psychiatryonline.org/doi/full/10.1176/appi.pn.2023.11.11.29
  56. https://www.nature.com/articles/s41598-020-67318-6
  57. https://www.sciencedirect.com/science/article/abs/pii/S0924977X17308970
  58. https://www.fda.gov/news-events/fda-brief/fda-brief-fda-requires-new-warnings-gabapentinoids-about-risk-respiratory-depression
  59. https://www.overdosefreepa.org/gabapentin-background-report/
  60. https://www.deadiversion.usdoj.gov/drug_chem_info/gabapentin.pdf
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC6533441/
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC6103607/
  63. https://www.drugs.com/medical-answers/gabapentin-narcotic-controlled-substance-3555993/
  64. https://pubmed.ncbi.nlm.nih.gov/26721643/
  65. https://agsjournals.onlinelibrary.wiley.com/doi/10.1111/jgs.12427
  66. https://pubmed.ncbi.nlm.nih.gov/15898970/
  67. https://pmc.ncbi.nlm.nih.gov/articles/PMC7265598/
  68. https://pmc.ncbi.nlm.nih.gov/articles/PMC4804325/
  69. https://pubmed.ncbi.nlm.nih.gov/11306709/
  70. https://www.pnas.org/doi/10.1073/pnas.0708930105
  71. https://synapse.patsnap.com/article/what-is-the-mechanism-of-gabapentin
  72. https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/10.1046/j.0003-2409.2001.02399.x
  73. https://www.sciencedirect.com/science/article/pii/S1471489205001906
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC3499716/
  75. https://pubmed.ncbi.nlm.nih.gov/9551785/
  76. https://www.sciencedirect.com/science/article/pii/S0092867409011854
  77. https://www.sciencedirect.com/science/article/abs/pii/S0920121197000843
  78. https://pubmed.ncbi.nlm.nih.gov/22240839/
  79. https://go.drugbank.com/drugs/DB00996/
  80. https://pubmed.ncbi.nlm.nih.gov/8022536/
  81. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020235s050%2C020882s035%2C021129s033lbl.pdf
  82. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-397.pdf_Neurontin_Pharmr.pdf
  83. https://pubmed.ncbi.nlm.nih.gov/12199720/
  84. https://pubmed.ncbi.nlm.nih.gov/11440340/
  85. https://www.sciencedirect.com/science/article/pii/S0021925818979214
  86. https://journals.sagepub.com/doi/10.1177/106002809402801011
  87. https://bpspubs.onlinelibrary.wiley.com/doi/10.1038/sj.bjp.0701320
  88. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021129s029lbl.pdf
  89. https://www.acs.org/molecule-of-the-week/archive/g/gabapentin.html
  90. https://www.drugfuture.com/chemdata/gabapentin.html
  91. https://www.chemspider.com/Chemical-Structure.3328.html
  92. https://patents.google.com/patent/US20080103334A1/en
  93. https://www.chemicalbook.com/synthesis/gabapentin.htm
  94. https://patents.google.com/patent/EP3604272A1/en
  95. https://www.pipelinepharma.com/blog/understanding-the-gabapentin-manufacturing-process
  96. https://www.sciencedirect.com/science/article/abs/pii/S0009250917305249
  97. https://onlinelibrary.wiley.com/doi/10.1002/9781119155560.ch2
  98. https://www.chemistryworld.com/podcasts/gabapentin/1017577.article
  99. https://pmc.ncbi.nlm.nih.gov/articles/PMC6131675/
  100. https://www.sciencedirect.com/topics/chemistry/gabapentin
  101. https://jamanetwork.com/journals/jama/fullarticle/188226
  102. https://pmc.ncbi.nlm.nih.gov/articles/PMC7897667/
  103. https://www.medlink.com/articles/gabapentin
  104. https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020235S011.pdf
  105. https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21216lbl.pdf
  106. https://sukl.gov.cz/wp-content/uploads/2025/02/Gabapentinum-PAR-45.pdf
  107. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-397.pdf_Neurontin_Medr_P1.pdf
  108. https://link.springer.com/article/10.1007/s11606-021-07314-2
  109. https://americanaddictioncenters.org/neurontin-abuse
  110. https://www.gov.uk/drug-safety-update/gabapentin-neurontin-risk-of-severe-respiratory-depression
  111. https://www.edaegypt.gov.eg/media/3nslozct/safety-alerts-gabapentin-skin-reaction.pdf
  112. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-216_20-235S15_20-882S2_21-129S5_Neurontin.cfm
  113. https://www.drugs.com/history/gralise.html
  114. https://www.goodrx.com/gabapentin/is-gabapentin-a-controlled-substance
  115. https://pmc.ncbi.nlm.nih.gov/articles/PMC9585149/
  116. https://www.pharmacist.com/DesktopModules/EasyDNNNews/DocumentDownload.ashx?portalid=0&moduleid=3675&articleid=2375&documentid=746
  117. https://products.mhra.gov.uk/product?product=GABAPENTIN%2520MILPHARM%2520300%2520MG%2520CAPSULES%2520HARD
  118. https://www.gov.uk/government/news/pregabalin-and-gabapentin-to-be-controlled-as-class-c-drugs
  119. https://www.gov.uk/drug-safety-update/pregabalin-lyrica-gabapentin-neurontin-and-risk-of-abuse-and-dependence-new-scheduling-requirements-from-1-april
  120. https://www.gov.uk/government/publications/circular-0192018-control-of-pregabalin-and-gabapentin-under-the-misuse-of-drugs-act-1971/control-of-pregabalin-and-gabapentin-under-the-misuse-of-drugs-act-1971
  121. https://www.gov.uk/government/news/reclassification-of-pregabalin-and-gabapentin-to-schedule-3-drugs-from-1-april-2019
  122. https://www.england.nhs.uk/wp-content/uploads/2019/02/handling-pregabalin-and-gabapentin.pdf
  123. https://montpeliersurgery.co.uk/gabapentin-and-pregabalin-legislation/
  124. https://www.gov.uk/drug-driving-law
  125. https://www.legislation.gov.uk/ukpga/1988/52/section/4
  126. https://questions-statements.parliament.uk/written-questions/detail/2025-07-15/68010/
  127. https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-gabapentin-assessing-potential-risk-serious-breathing.html
  128. https://canadiancentreforaddictions.org/pregabalin-vs-gabapentin-addiction/
  129. https://australianprescriber.tg.org.au/articles/gabapentinoids-a-therapeutic-review.html
  130. https://www.tga.gov.au/safety-and-shortages/safety-monitoring-and-information/safety-alerts/pregabalin-and-gabapentin
  131. https://www.health.vic.gov.au/drugs-and-poisons/medicines-and-poisons-recent-updates
  132. https://www.ema.europa.eu/en/medicines/human/referrals/neurontin
  133. https://www.petmd.com/pet-medication/gabapentin
  134. https://www.avma.org/news/north-carolina-law-will-require-veterinarians-report-gabapentin-use
  135. https://www.ncdhhs.gov/divisions/mental-health-developmental-disabilities-and-substance-use-services/north-carolina-drug-control-unit/north-carolina-controlled-substances-act/nc-controlled-substances-reporting-system-legal-updates
  136. https://pmc.ncbi.nlm.nih.gov/articles/PMC9790257/
  137. https://www.singlecare.com/blog/gabapentin-dosage-for-dogs-by-weight/
  138. https://journalofethics.ama-assn.org/article/neurontin-and-label-marketing/2006-06
  139. https://www.acpjournals.org/doi/10.7326/0003-4819-145-4-200608150-00008
  140. https://pmc.ncbi.nlm.nih.gov/articles/PMC416587/
  141. https://www.npr.org/2003/01/16/920362/the-selling-of-neurontin
  142. https://www.justice.gov/archive/opa/pr/2004/May/04_civ_322.htm
  143. https://psychiatryonline.org/doi/full/10.1176/pn.44.19.0001
  144. https://www.koskoff.com/related-stories/neurontin/
  145. https://topclassactions.com/lawsuit-settlements/lawsuit-news/325m-neurontin-class-action-settlement-reached-third-party-payors/
  146. https://www.healthaffairs.org/doi/abs/10.1377/hlthaff.2011.0370
  147. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879613/
  148. https://www.nytimes.com/2004/05/14/business/pfizer-to-pay-430-million-over-promoting-drug-to-doctors.html
  149. https://www.hsrd.research.va.gov/research/citations/pubbriefs/articles.cfm?RecordID=69
  150. https://www.reuters.com/article/business/healthcare-pharmaceuticals/pfizer-to-pay-325-million-in-neurontin-settlement-idUSKBN0ED1IR/
  151. https://topclassactions.com/lawsuit-settlements/lawsuit-news/pfizer-settle-neurontin-antitrust-class-action-lawsuit-190m/
  152. https://www.reuters.com/article/business/healthcare-pharmaceuticals/court-upholds-142-million-verdict-against-pfizer-over-neurontin-idUSBRE93303S/
  153. https://www.medpagetoday.com/neurology/generalneurology/117705
  154. https://www.acpjournals.org/doi/abs/10.7326/ANNALS-25-01750
  155. https://www.drugs.com/news/rate-gabapentin-increasing-since-2010-127007.html
  156. https://www.nature.com/articles/s41467-023-40637-8
  157. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2798312
  158. https://injepijournal.biomedcentral.com/articles/10.1186/s40621-024-00547-9
  159. https://www.thelancet.com/journals/lanam/article/PIIS2667-193X%2822%2900119-3/fulltext
  160. https://gaspsdata.dbhdd.ga.gov/data/trends-gabapentin-detection-and-involvement-drug-overdose-deaths
  161. https://pubmed.ncbi.nlm.nih.gov/39916737/
  162. https://www.goodrx.com/gabapentin
Add your contribution
Related Hubs
User Avatar
No comments yet.